化学信息：

中文名	黄芪甲苷
英文名	Astragaloside IV
中文别名	黄芪甙；黄芪皂苷 IV
英文别名	Astrasieversianin XIV; Cyclosieversioside F; Cyclosiversioside F; Astramembrannin I; Astragaloside A
来源	蒙古黄耆Astragalus mongholicus Bunge
化合物类型	萜类(Terpenoids)>三萜>羊毛甾烷型四环三萜皂苷
化学式	C41H68O14
分子量	784.97
CAS号	84687-43-4
纯度	98%, HPLC
溶剂/溶解度	DMSO: ≥ 100 mg/ml (127.39 mM)
溶液配制	10mg加入1.27l DMSO，或者每7.85mg加入1ml DMSO，配制成10mM溶液。

生物信息

产品描述	Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.
信号通路	-
靶点	MMP-2	MMP-9	ERK1	ERK2	JNK
IC50	-	-	-	-	-
体外研究	Astragaloside IV (10, 20, 40 ng/ml) inhibits NSCLC cell growth, whereas low concentrations of astragaloside IV (1, 2.5, 5 ng/ml) has no obvious cytotoxicity on cell viability. Moreover, combined treatment with astragaloside IV significantly increases chemosensitivity to cisplatin in NSCLC cells. On the molecular level, astragaloside IV co-treatment significantly inhibits the mRNA and protein levels of B7-H3 in the presence of cisplatin. Astragaloside IV inhibits the viability and invasive potential of MDA-MB-231 breast cancer cells, suppresses the activation of the mitogen activated protein kinase (MAPK) family members ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2 and -9.
体内研究	Astragaloside IV (10, 20 mg/kg, p.o.) exhibits a potent ability to prevent cognitive deficits induced by transient cerebral ischemia and reperfusion. Astragaloside IV (10 mg/kg) and Astragaloside IV (20 mg/kg) can significantly decrease the levels of these cytokines compared to the Model group. Astragaloside IV significantly inhibits the level of TLR4 and its downstream proteins, suggesting that both MyD88-dependent and -independent pathways play important roles in the anti-inflammatory effects of Astragaloside IV. Astragaloside IV attenuates NLRP3 and cleaved-caspase-1 expression, and reduces Iba1 protein expression. In the mice model, the high-dose astragaloside IV group has a significant increase in the 48-hour survival rate [60% (9/15) vs 13.3% (2/15), P < 0.05], significant reductions in the serum ALT and AST levels (P < 0.01), and significant reductions in liver histopathological indices and the degree of apoptosis of hepatocytes (P < 0.01), as well as a significant reduction in the content of MDA in liver homogenate (P < 0.01) and a significant increase in the activity of SOD.
临床实验	N/A

参考文献：

1.Li M, et al. Neurosci Lett. 2017,639:114-119.

2.He CS, et al. Cell Physiol Biochem. 2016,40(5):1221-1229.

3.Liu L, et al. Zhonghua Gan Zang Bing Za Zhi. 2016,24(10):772-777.

4.Jiang K, et al. Int Immunopharmacol. 2016,42:195-20.

包装清单：

产品编号	产品名称	包装
SM6152-10mM	黄芪甲苷(98%, HPLC)	10mM×0.2ml
SM6152-25mg	黄芪甲苷(98%, HPLC)	25mg
SM6152-100mg	黄芪甲苷(98%, HPLC)	100mg
－	说明书	1份

保存条件：

-20℃保存，至少一年有效。固体粉末4℃保存，至少一个月有效。如果溶于非DMSO溶剂，建议分装后-80℃保存，预计6个月内有效。

注意事项：

本产品可能对人体有一定的毒害作用，请注意适当防护，以避免直接接触人体或吸入体内。

本产品仅限于专业人员的科学研究用，不得用于临床诊断或治疗，不得用于食品或药品，不得存放于普通住宅内。

为了您的安全和健康，请穿实验服并戴一次性手套操作。

使用说明：
1.收到产品后请立即按照说明书推荐的条件保存。使用前可以在2,000-10,000g离心数秒，以使液体或粉末充分沉降至管底后再开盖使用。
2.对于10mM溶液，可直接稀释使用。对于固体，请根据本产品的溶解性及实验目的选择相应溶剂配制成高浓度的储备液(母液)后使用。
3.具体的最佳工作浓度请参考本说明书中的体外、体内研究结果或其它相关文献，或者根据实验目的，以及所培养的特定细胞和组织，通过实验进行摸索和优化。
4.不同实验动物依据体表面积的等效剂量转换表请参考如下网页：
https://www.beyotime.com/support/animal-dose.htm